About
About Caplin Point Laboratories Limited
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel, capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag, inhalers, and sprays and IV infusion. It also provides dry and syrups, lyophilized vials, prefilled syringes, emulsion injection, ophthalmic droppers, sachets, liquid injectables, topicals, pre-filled syringes, and pre-mix bags. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India.
Research context
Caplin Point Laboratories Limited appears in PyInvesting’s India Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Visit company website
5 years, 6 months ago
Caplin Point Laboratories Limited is currently in a long term uptrend where the price is trading 29.7% above its 200 day moving average.
From a valuation standpoint, the stock is 26.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.5.
Caplin Point Laboratories Limited's total revenue rose by 20.2% to $3B since the same quarter in the previous year.
Its net income has increased by 10.1% to $645M since the same quarter in the previous year.
Finally, its free cash flow grew by 286.9% to $2B since the same quarter in the previous year.
Based on the above factors, Caplin Point Laboratories Limited gets an overall score of 5/5.